I’d also like to point out that currency losses were 1.8 million during the quarter or $0.04 per diluted share excluding the currency impact adjusted earnings would’ve been $0.61 per diluted share in the quarter.The euro volatility particularly impacted our biomedical business which largely manufactured that U.S. itself approximately 45% of its product in Europe. Sales for the quarter were 240 million, which represents a new quarterly record and an increase of 20% compared to net sales of 201 million a year ago.
Chart Industries' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts